GLP-1s and Ramadan 2027: what UAE and Gulf research says

GLP-1 Ramadan UAE: why the 2027 question matters

For people researching Ozempic, Mounjaro or Wegovy during Ramadan, the practical question is how an existing medicine interacts with a day without food or fluids. It is different from asking whether intermittent fasting improves weight loss. Ramadan also changes the timing of meals, sleep and daily activity; a study that measures body weight alone cannot settle all of those questions.

The UAE’s expected first fasting day for Ramadan 2027 is 8 February 2027, subject to official moon-sighting confirmation. This is a forecast, not an announced religious date.^[5] A February Ramadan should not be described as a UAE summer fast. Fluid loss, outdoor work and travel remain relevant, but there is no basis for borrowing summer heat claims to predict everyone’s February risk.

The UAE has direct involvement in Ramadan diabetes research. That makes the Gulf evidence more useful locally than a generic weight-loss comparison, while still leaving limits on who the findings apply to. For the wider context, see our UAE obesity and GLP-1 research landscape.

GLP-1, GIP and glucagon during a fasting day

Semaglutide activates the GLP-1 receptor. Its glucose-lowering effect includes stimulating insulin and reducing glucagon secretion when glucose is high. It also affects appetite and slows early post-meal gastric emptying. The glucose dependence helps explain why a GLP-1 medicine is not equivalent to a fixed supply of insulin, but it does not make hypoglycaemia impossible, particularly with other diabetes medicines.^[3]

Tirzepatide activates GIP and GLP-1 receptors.^[8] Retatrutide adds glucagon-receptor activity to that combination. Counting receptors is not a Ramadan safety ranking: a third receptor does not prove better protection during fasting. Retatrutide’s clinical development and receptor profile are discussed separately in the GLP-1, GIP and glucagon mechanism review.^[4]

During Ramadan, the research problem spans both the daytime fast and the eating window between iftar and suhoor. Appetite reduction, gastrointestinal symptoms and altered meal patterns can overlap. These mechanisms explain what investigators need to measure; they cannot tell an individual whether fasting is suitable or which medicine to choose.

What O-SEMA-FAST actually found

O-SEMA-FAST was a prospective, non-interventional study conducted during Ramadan 2023 in the UAE, Saudi Arabia and Kuwait, published in 2025. The final analysis included 257 adults with type 2 diabetes already receiving oral semaglutide. Follow-up covered approximately 20 weeks, including time before and after Ramadan.^[1]

From baseline to the end of follow-up, the reported average HbA1c change was −0.2 percentage points and weight change was −2.6 kg. These are whole-follow-up findings, not weight lost during Ramadan alone. There was no randomized non-fasting control group, so the study cannot separate a fasting effect from medication, adherence or other changes in care.

Among 216 participants with available self-reported hypoglycaemia data, 67 (31.0%) reported events. No severe events were reported; gastrointestinal disorders were the most common adverse effects. The 31.0% figure describes the available-data group across the study’s reporting periods, not a proven semaglutide-caused Ramadan event rate. Other diabetes medicines and differences between participants matter.

It is also an oral-formulation study. It should not be retitled an “Ozempic injection trial”, used as a Wegovy obesity trial, or treated as evidence for research peptides. Its strongest contribution is a real-world account of selected Gulf patients with type 2 diabetes under clinical care, including the limits of self-reported events and incomplete diaries.

Mounjaro during Ramadan: what T-RAM can tell us

Lilly’s T-RAM study (NCT06635057) examines tirzepatide in adults with type 2 diabetes around Ramadan. The registry describes a Phase 4, open-label, single-arm study, with actual enrollment of 166 participants. It records completion on 15 April 2026; the record was last updated on 22 May 2026.^[2]

At our 25 October 2026 check, ClinicalTrials.gov showed no results posted. Completion means the study has finished according to the registration; it does not reveal its safety or effectiveness findings. T-RAM therefore belongs in an evidence-watch section, not a table of proven benefits.

Before using a later report, the relevant checks are the number analyzed, background medicines, how low-glucose events were defined, gastrointestinal adverse events, and the timing of outcome measurements. A sponsor announcement, conference abstract and peer-reviewed paper may offer different levels of detail. None should be silently substituted for another.

Dehydration, low glucose and gastrointestinal symptoms

The important distinction is between a medicine’s usual adverse-effect profile and risks introduced or amplified by fasting. The cited UK Ozempic Summary of Product Characteristics identifies nausea, vomiting and diarrhoea as possible contributors to dehydration and notes the potential for deterioration in renal function. It also identifies greater hypoglycaemia risk with insulin or sulfonylureas.^[3]

A day without fluid intake can make fluid-loss symptoms more consequential. Reduced appetite does not establish adequate nutrition, and an absence of hunger does not demonstrate safe glucose levels. The combination of a medicine, kidney function, previous low-glucose events and other treatments is more informative than the brand name alone.

General comparisons are covered in our Ozempic, Mounjaro and Wegovy side-effect review. The baseline blood-test evidence review explains why glucose control and kidney-related measurements appear in clinical assessments. Neither page replaces a Ramadan-specific medical assessment.

Retatrutide and Ramadan: the unanswered questions

Retatrutide remains an investigational molecule in Lilly’s cited clinical-development material. Its GLP-1, GIP and glucagon activity is scientifically relevant, but no Ramadan-specific retatrutide outcome study was identified in targeted PubMed and ClinicalTrials.gov searches on 25 October 2026.^[4][9][10]

That is a bounded evidence gap, not proof that no unpublished data exist. General obesity or diabetes results cannot establish how prolonged daytime abstinence from fluids affects tolerability, glucose patterns or retention in a retatrutide study. It would be particularly misleading to combine oral semaglutide findings with retatrutide weight-loss headlines and label the result a fasting protocol.

Our TRANSCEND-T2D-1 research review covers the diabetes trial on its own terms. Remy Research laboratory materials are for in-vitro research only, not human or veterinary use; clinical findings about regulated study medicines do not establish human-use suitability for laboratory products.

Cold-chain and storage questions over Ramadan

Ramadan does not change a product’s validated storage requirements. The relevant variables are the exact formulation and pack, whether it has been opened, temperature exposure, light and freezing. A published room-temperature allowance for one presentation cannot be transferred to another pen, an oral tablet or a research vial.

For example, the cited UK Ozempic injection product information specifies refrigerated storage before use and says not to freeze the product. Its in-use conditions are formulation-specific. This is a manufacturer-label example, not a UAE pack-specific instruction: the supplied local leaflet and pharmacist are the appropriate sources for an actual medicine.^[3]

A longer journey around iftar, an unattended delivery or contact with frozen packs raises a temperature-history question, not a reason to assume either damage or stability. A cold parcel on arrival does not reconstruct every earlier temperature. Our peptide stability and storage guide explains the analytical distinction between general storage advice and measured stability evidence. Laboratory material handling and prescription-medicine storage remain separate subjects.

The clinician perspective: assessment before Ramadan

In a University of Sharjah conference report, Prof. Mohamed Hassanein, identified there with the Dubai Health Authority, puts it simply: Ramadan needs planning. The report does not display a publication date, so this is a general clinician perspective rather than a new Ramadan 2027 DHA recommendation.^[7]

The IDF-DAR practical-guidelines authors state: It is of paramount importance that people with diabetes that fast are given the appropriate guidance and receive proper care.^[6] These statements support individualized assessment; they do not endorse a specific GLP-1 brand or a self-directed Ramadan regimen.

Medical suitability and religious fasting validity are distinct. The clinical literature can describe glucose outcomes and adverse events, but it cannot answer a religious ruling for every formulation. The questions below keep that boundary explicit.